No profile data available.
Fennec Pharmaceuticals Inc. (FENC) is a healthcare company in the poison treatment pharmaceuticals industry, based in Research Triangle Park, United States, with about 35 full-time employees.
It reported revenue of $44.64 million for fiscal year 2025, down 6.1% from fiscal year 2024, and net income of -$9.74 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $17.87 million, up 85.2% from a year before. Its market capitalization was $372.76 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 8, 2026.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients.
Fennec Pharmaceuticals reported $44.64 million in revenue for fiscal year 2025, down 6.1% from $47.54 million in fiscal year 2024. In Q2 2026 revenue was $17.87 million.
$372.76 million as of October 8, 2026.
Listed companies of a similar size in the same industry (poison treatment pharmaceuticals) include Indivior PLC (INDV), Achieve Life Sciences, Inc. (ACHV), Aquestive Therapeutics, Inc. (AQST), Anebulo Pharmaceuticals, Inc. (ANEB).